思美泰治疗慢性病毒性肝炎合并胆汁淤积疗效观察

摘要

Objective: To explore clinical efficacy of Transmetil therapy on chronic virus hepatitis with intra-hepatic cholestasis. Methods: 180 cases with chronic virus hepatitis with intra-hepatic cholestasis were randomly divided into three groups: group A, group B and control group (60 case in each group), patients in group A received basic treatment plus Transmetil (1 000 mg, once daily); patients in group B received basic treatment plus Transmetil (2 000 mg, once daily;patients in control group received only basic treatment (diammonium glycyrrhizinate, reduced glutathione, potassium magnesium aspartate, Vitamin K1). The symptoms, signs and live functions of these patients were observed after treatment. Results: Patients in group A and group B responsed better than patients in control group in terms of improvement of symptoms, signs and live functions (P＜0.05 or P＜0.01). Patients in group B responsed better than patients in group A in terms of reduce in TBIL , GGT , ALP in live functions (P＜0.05). No Transmetil related side effects were observed. Conclusion: Clinical efficacy of Transmetil therapy on chronic virus hepatitis with intra-hepatic cholestasis is good, higher dosage of Transmetil can achieve better reponse.%目的:观察思美泰对慢性病毒性肝炎合并胆汁淤积的疗效.方法:将180例患者随机分为A治疗组、B治疗组、对照组各60例.对照组给予甘草酸二铵、还原型谷胱甘肽、门冬氨酸钾镁、维生素K1综合治疗.在综合治疗的基础上,A治疗组加用思美泰1 000 mg,B治疗组加用思美泰2 000 mg.观察三组治疗前后临床症状、体征及肝功能指标的变化.结果:A治疗组与B治疗组在改善临床症状、体征及肝功能指标方面与对照组比较差异有统计学意义(P<0.05或P<0.01);B治疗组在降低TBIL、GGT、ALP方面与A治疗组比较差异有统计学意义(P<0.05);治疗过程中未发现思美泰相关的不良反应.结论:思美泰治疗慢性病毒性肝炎合并胆汁淤积效果较好,且适当增加剂量可提高疗效,安全性较好.